BiotechTube

Satralizumab

Phase 3Recruiting
1 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuromyelitis Optica Spectrum Disorder

Conditions

Neuromyelitis Optica Spectrum Disorder, NMOSD

Trial Timeline

Mar 31, 2026 → Sep 12, 2029

NCT ID
NCT05199688

About Satralizumab

Satralizumab is a phase 3 stage product being developed by Roche for Neuromyelitis Optica Spectrum Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05199688. Target conditions include Neuromyelitis Optica Spectrum Disorder, NMOSD.

What happened to similar drugs?

2 of 5 similar drugs in Neuromyelitis Optica Spectrum Disorder were approved

Approved (2) Terminated (1) Active (3)
✅Satralizumab 120 mgChugai PharmaceuticalApproved
✅InebilizumabAmgenApproved
🔄Satralizumab + Placebo + Baseline TreatmentChugai PharmaceuticalPhase 3
🔄Satralizumab + PlaceboChugai PharmaceuticalPhase 3
🔄satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroidsRochePhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05199688Phase 3Recruiting
NCT06450639Phase 2Recruiting

Competing Products

8 competing products in Neuromyelitis Optica Spectrum Disorder

See all competitors
ProductCompanyStageHype Score
Satralizumab 120 mgChugai PharmaceuticalApproved
35
Satralizumab + Placebo + Baseline TreatmentChugai PharmaceuticalPhase 3
40
Satralizumab + PlaceboChugai PharmaceuticalPhase 3
40
satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroidsRochePhase 3
40
UPLIZNAAmgenPre-clinical
33
InebilizumabAmgenPhase 2
42
InebilizumabAmgenApproved
47
intravenous methylprednisoloneBrain BiotechPre-clinical
23